论文部分内容阅读
目的:对乳腺癌改良根治术化疗后的预后相关影响因素进行分析。方法:选择台山市中医院2011年1月至2013年1月接收治疗乳腺癌患者120例,以患者病理分析、术后是否化疗、激素受体状况为依据,将患者分为10组:Ⅰ期化疗组(12例)与Ⅰ期非化疗组(12例),激素受体是ER和(或)PR(+)的II期化疗组(12例)与非化疗组(12例),激素受体是ER和(或)PR(-)的II期化疗组(12例)与非化疗组(12例),激素受体是ER和(或)PR(+)的Ⅲ期化疗组(12例)与Ⅲ期非化疗组(12例),激素受体是ER和(或)PR(-)的化疗组(12例)与非化疗组(12例),对各组患者预后进行分析。结果:Ⅰ期两组患者局控率、生存率差异无统计学意义(P>0.05),激素受体是ER和(或)PR(+)的II期化疗组与非化疗组3年局控率与生存率比较,差异无统计学意义(P>0.05),激素受体是ER和(或)PR(-)的II期化疗组3年局控率、生存率明显比非化疗组高,Ⅲ期患者两个化疗组局控率、生存率明显比非化疗组高,组间比较,差异具有统计学意义(P<0.05)。结论:乳腺癌根治术后化疗效果最为主要的影响因素是患者病理分期及激素受体,临床上在确定改良根治术后是否需要化疗时,应该充分考虑以上因素。
Objective: To analyze the prognostic factors of modified radical mastectomy for breast cancer. Methods: A total of 120 patients with breast cancer were recruited from Taichung Hospital of Traditional Chinese Medicine from January 2011 to January 2013. The patients were divided into 10 groups according to their pathological analysis, postoperative chemotherapy and hormone receptor status. Stage Ⅰ The patients in the chemotherapy group (12 cases) and the non-chemotherapy group (12 cases), the hormone receptor in the ER group and / or PR (+) group (12 cases) and the non-chemotherapy group (12 cases) The patients in the phase II group (n = 12) and the non-chemotherapy group (n = 12) had ER and / or PR (- ) And Ⅲ non-chemotherapy group (12 cases), hormone receptor ER and / or PR (-) chemotherapy group (12 cases) and non-chemotherapy group (12 cases), the prognosis of each group were analyzed. Results: There was no significant difference in the control rate and survival rate between the two groups (P> 0.05). The hormone receptor was ER and / or PR (+) in the phase II chemotherapy and non-chemotherapy groups for 3 years (P> 0.05). The hormone receptor was ER and / or PR (-) in the phase II chemotherapy group for 3 years. The survival rate was significantly higher than that of the non-chemotherapy group, The two groups chemotherapy rate and survival rate were significantly higher than those in the non-chemotherapy group. The difference between the two groups was statistically significant (P <0.05). Conclusion: The most important influencing factor of chemotherapy after radical mastectomy is the pathological staging of patients and the hormone receptor. In clinical practice, the above factors should be fully taken into account in determining whether chemotherapy is needed after the modified radical mastectomy.